Key Highlights
- CMS announced final 2027 Medicare Advantage payment rules showing a 2.48% net average increase — representing more than $13 billion in additional sector funding
- Shares of CVS climbed up to 5.20% during Tuesday’s session as investors viewed the news favorably for the Aetna division
- The 2024 risk-adjustment model will remain in effect for 2027, with stricter regulations on unlinked chart review diagnoses
- Cantor Fitzgerald maintained its Overweight stance with a $95 target, highlighting Medicare Advantage margin improvement as a catalyst
- The company’s Q1 2026 earnings release is scheduled for May 6, with analyst consensus calling for $2.23 EPS and $94.86 billion in revenue
CVS Health experienced a notable rally on Tuesday following a Medicare Advantage policy announcement from federal regulators that lifted managed-care stocks across the board.
The Centers for Medicare & Medicaid Services released its finalized 2027 payment policies for Medicare Advantage and Part D programs, revealing a projected net average rate increase of 2.48% — equating to over $13 billion in incremental funding industry-wide for the 2027 calendar year.
For CVS, the implications are significant. The company operates substantial Medicare Advantage exposure through Aetna, complementing its pharmacy benefit management and retail drugstore segments.
Investors responded enthusiastically to the announcement. Shares surged as much as 5.20% during Tuesday’s trading session.
Regulatory Details Bring Nuanced Impact
The policy update contained important details beyond the headline rate increase. CMS indicated it would maintain the 2024 risk-adjustment model through 2027 and implement restrictions on diagnoses derived from unlinked chart reviews in risk-score computations.
This represents a more stringent framework that could impact insurers relying heavily on coding-intensive reimbursement approaches. However, CVS investors appeared to prioritize the positive funding news over the regulatory nuances given the company’s diversified business model.
CVS has also seen progress in its Stars ratings performance. After a steep decline from 85% bonus-eligible Stars scores in 2022 to just 21% in 2023 — a period that significantly pressured Medicare Advantage profitability — the trajectory has been improving.
Cantor Fitzgerald, which reaffirmed its Overweight rating and $95 price objective on Monday, noted that while the Medicare Advantage segment still needs to reach 3% margin levels, 2026 individual Medicare Advantage margins are approaching breakeven profitability.
Prior to Tuesday’s advance, shares were changing hands at $73.28, a valuation multiple analysts consider attractive relative to intrinsic value.
Wall Street Maintains Positive Outlook Ahead of Earnings
Analyst sentiment on CVS remains predominantly favorable. The stock holds a consensus Buy rating with a mean price target of $92.79.
Recent rating activity includes Bernstein elevating shares to Outperform with a $94 objective in March, Piper Sandler maintaining Overweight while adjusting its target to $99, and Argus Research continuing its Buy recommendation at $90.
Leerink Partners also carries an Outperform rating with a $98 target, influenced partly by the recent FTC consent decree concerning Caremark and Zinc, which analysts interpreted as reducing regulatory overhang.
On the corporate development front, CVS recently disclosed an asset purchase arrangement with GenieRx Holdings, designating GenieRx as the stalking horse bidder in the bankruptcy sale of Omnicare.
The healthcare giant also added John E. Gallina, former CFO of Elevance Health, to its board of directors and audit committee.
Looking ahead: CVS is set to release Q1 2026 results on May 6. Wall Street consensus forecasts call for earnings per share of $2.23 on revenue of $94.86 billion.
